1. Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
- Author
-
Iokfai Cheang, Shi Shi, Xinyi Lu, Shengen Liao, Xu Zhu, Xi Su, Qi Lu, Jing Yuan, Dachun Xu, Min Zhang, Cuilian Dai, Jingfeng Wang, Fang Yuan, Yan Zhao, Jingmin Zhou, and Xinli Li
- Subjects
Heart Failure ,China ,Tetrazoles ,Pharmaceutical Science ,Stroke Volume ,Angiotensin Receptor Antagonists ,Ventricular Dysfunction, Left ,Genetics ,Humans ,Valsartan ,Molecular Medicine ,Neprilysin ,Cardiology and Cardiovascular Medicine ,Genetics (clinical) - Abstract
This study aims to investigate the dosage pattern, efficacy, and safety of sacubitril/valsartan (Sac/Val) in Chinese heart failure with reduced ejection fraction (HFrEF) patients regarding real-world settings. Patients from 27 centers with a confirmed diagnosis of HFrEF and initiated Sac/Val treatment were enrolled. The primary objective was to evaluate the dosage pattern and change of heart failure status. In a final cohort of 983 patients, outpatient Sac/Val treatment demonstrated a similar beneficial effect in NT-proBNP and cardiac function. After initiating the treatment, overall and sub-population showed similar safety and efficacy. Patients who received a higher dose of Sac/Val (> 200 mg/d) demonstrated better improvement in LV function and reduction of NT-proBNP regardless of adjustment. Among Chinese HFrEF patients, Sac/Val showed a comparable reduction in NT-proBNP and improvement in cardiac function. Data further support guideline recommendations of Sac/Val in Chinese population. Optimal up-titration might provide further benefits. Further long-term and prognostic studies are needed. Graphical abstract
- Published
- 2022
- Full Text
- View/download PDF